BIT:DIAMedical Equipment
DiaSorin (BIT:DIA) Could Be 2% Overvalued After Q2 Results And FDA Clearance
DiaSorin (BIT:DIA) is back in focus after its second quarter 2026 results, with revenue of €315 million and flat quarterly net income, along with fresh FDA clearance for a new Liaison NES assay in the U.S.
See our latest analysis for DiaSorin.
DiaSorin’s recent Q2 update and FDA clearance have arrived alongside a 90 day share price return of 23.85%, although the 1 year total shareholder return is down 15.07%. This indicates recent momentum following a weaker longer term experience.
If...